The Food and Drug Administration has released the first ever draft guidance on psychedelics Research, a move that was requested by bipartisan lawmakers through a bill only days before.
The bill was filed by Reps. Dan Crenshaw, Mariannette Miller-Meeks, and Ro Khanna in this month. FDA did not say that it was responding directly to the measure by releasing the guidance, but the first part of this bill specifically addressed that action.
Crenshaw, in a Thursday press release, said: “I am glad that the FDA has taken this first step by issuing guidance on psychedelic trials and listening to my bipartisan bill with Reps. Miller Meeks and Khanna.” It’s important that we get it right for the scientists who are doing this important work.
The congressman, a veteran of the military who has played a leading role in advancing psychedelics’ research, stated that “we need this guidance for expanding clinical trial access to push us towards life-saving psychedelic treatments for our veterans, servicesmembers, people with PTSD, traumatic head injury, and those living with substance abuse disorder.”
The FDA’s draft guidelines provide scientists with a framework for conducting research that may lead to the creation of psychedelic drugs. The public has 60 days to comment on the final guidance.
Miller-Meeks stated that “many Veterans find guided use psychedelics and assisted therapy to be a successful way to treat the excruciating post-traumatic pain.” As a doctor, I understand the importance of medical studies and am encouraged by FDA’s guidance and support for psychedelic trials. This is a significant step that gives Veterans hope and another option when they feel like they have exhausted all other methods of coping.
In recent years, interest in psychedelics grew exponentially as cities and state across the nation moved to promote research and remove criminal penalties. They also regulated access to substances like psilocybin or MDMA, which are both already designated as “breakthrough treatments” by FDA.
FDA stated that the draft guidance “describes fundamental considerations throughout drug development including trial conduct and data collection as well as subject safety, new drug application requirements, and drug application requirements.”
Khanna said, on his part, that the guidance provided by the agency “is an important step in protecting the well-being and health of veterans, including those with PTSD.”
He said: “I am proud to be a cosponsor of this bill, which will expand research into psychedelic therapy in hopes of improving many Americans’ health.”
Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.
Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.
—
The bipartisan bill of lawmakers called for the Secretary of Health and Human Services to issue draft guidance for the public on considerations when conducting clinical trials of psychedelic-assisted therapy. This includes how those seeking an exemption for investigational purposes for such clinical trial should request interactive assistance from the Food and Drug Administration.
If passed, the FDA would have been required to release this draft guidance within 180 calendar days. The agency, however, was clearly prepared to release the draft guidance much earlier. The bill also requires FDA to publish its final guidance document 180 days after publication of the draft. This may be enough for lawmakers to still want to advance the measure.
Veterans Exploring Treatment Solutions, VETS, said that there are still many questions about psychedelic assisted therapy. Unfortunately, due to administrative requirements relating to scheduling status, it can be difficult to research these compounds. We applaud efforts to reduce barriers to the research process and to help improve access to these life-saving therapies.
Crenshaw spoke about the bill at a hearing of the House Energy & Commerce Committee on the same day it was introduced. He referred to psychedelics in his remarks as a possible “solution” for the nation’s drug abuse problems.
The congressman stated that he is working to “get clinical trial guidance from the FDA for psychedelic therapy,” and that “this treatment will be revolutionary.” It has already been changed dozens lives.
“We’re talking about LSD trips from the 1960s. “This therapy is often repeated in a controlled environment and is overseen by a medical professional,” he explained. “And when it’s about the efficacy, the proof lies in the data and in the testimonials–but we have to wait for the FDA to release clinical trial guidelines for psychedelic-assisted therapy before the industry invests in this.”
In the FDA’s Federal Register submission, it is noted that a docket was made available to allow people to provide comments on this draft guidance.
It is timely that the move has been made, since lawmakers and health officials are interested in expanding research on psychedelics, after studies revealed their potential to treat conditions like severe depression, addiction, and post-traumatic disorder.
Marijuana Moment questioned HHS Secretary Xavier Becerra about the department’s thinking on psychedelics policy earlier this month. He said he had to “defer to” the expertise of NIDA, which is also under his agency. “I want to be sure that I touchbase with what they’ve done on that.”
NIDA has called for research this month into the impacts of changing laws surrounding psychedelics. This includes the effects of allowing controlled access to substances such as psilocybin.
NIDA announced separately in May that they are soliciting proposals for a series research initiatives to explore the use of psychedelics to treat drug abuse, and plan to fund relevant studies with $1.5 million.
In May, NIDA director Nora Volkow said that new evidence is emerging that psychedelics have “significant potential” to treat certain mental conditions. This topic is of “great interest” to researchers.
Congress has also called for reforms to psychedelics.
A powerful U.S. Senate committee has asked the U.S. Department of Veterans Affairs to investigate the therapeutic potential of psychoedelics.
A congressional committee on the House side recently approved a massive defense bill, which includes GOP-led provisions for creating a “medical marijuana pilot program” and requiring a study of the therapeutic potential of psychoedelics among active duty military personnel under the U.S. Department of Defense.
According to a recent national survey , nearly half of American voters believe that possession for personal use should not be criminalized.
In an unexpected twist, the younger brother of President Joe Biden revealed this week that he is ‘very open-minded’ about the use psychedelic drugs for addiction treatment.
Op-Ed: How to Save Marijuana Social Equity programs from the Supreme Court’s Affirmative Action Ruling
Photo by Dick Culbert.
The post Bipartisan Legislators Applaud FDA for Publishing Psychedelics Guidance as They Requested in New Congressional Bill first appeared on Marijuana Minute.
